|
|
||||||||
1From the Departments of Ophthalmology and 2Surgery, College of Physicians and Surgeons, and the 3Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York.
PURPOSE. The receptor for advanced glycation end products (AGEs) has been implicated in the pathogenesis of diabetic complications. This study was conducted to characterize the role of the RAGE axis in a murine model of nonproliferative diabetic retinopathy (NPDR).
METHODS. The retinas of hyperglycemic, hyperlipidemic (HGHL, apolipoprotein E/ db/db) mice were examined for the development of early retinal vascular lesions of NPDR and compared to littermates at 6 months of age. Neural function was assessed with electroretinography. Immunohistochemistry, real-time RT-PCR, autofluorescence, and ELISA studies were used to localize and quantify the AGE/RAGE axis. Soluble RAGE, a competitor of cellular RAGE for its ligands, was administered to assess the impact of RAGE blockade.
RESULTS. Early inner retinal neuronal dysfunction, manifested by prolonged latencies of the oscillatory potentials and b-wave, was detected in hyperglycemic mice. HGHL mice exhibited accelerated development of acellular capillaries and pericyte ghosts compared with littermate control animals. AGEs were localized primarily to the vitreous cavity and internal limiting membrane (ILM) of the retina, where they were intimately associated with the footplates of RAGE-expressing Müller cells. AGE accumulation measured by ELISA was increased within the retinal extracellular matrix of hyperglycemic mice. AGE fluorescence and upregulation of RAGE transcripts was highest in the retinas of HGHL mice, and attenuation of the RAGE axis with soluble RAGE ameliorated neuronal dysfunction and reduced the development of capillary lesions in these mice.
CONCLUSIONS. In early diabetic retinopathy, the RAGE axis, comprising the cellular receptor and its AGE ligands, is amplified within the retina and is accentuated along the vitreoretinal interface. Antagonism of the RAGE axis in NPDR reduces neurovascular perturbations, providing an important therapeutic target for intervention.
This article has been cited by other articles:
![]() |
J. J. Steinle, S. Sharma, C. P. Smith, and L. S. McFayden-Ketchum Normal Aging Involves Modulation of Specific Inflammatory Markers in the Rat Retina and Choroid J Gerontol A Biol Sci Med Sci, March 1, 2009; 64A(3): 325 - 331. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Kern and A. J. Barber Retinal ganglion cells in diabetes J. Physiol., September 15, 2008; 586(18): 4401 - 4408. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Bhatwadekar, J V Glenn, J L Figarola, S Scott, T A Gardiner, S Rahbar, and A W Stitt A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats Br. J. Ophthalmol., April 1, 2008; 92(4): 545 - 547. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Tezel, C. Luo, and X. Yang Accelerated Aging in Glaucoma: Immunohistochemical Assessment of Advanced Glycation End Products in the Human Retina and Optic Nerve Head Invest. Ophthalmol. Vis. Sci., March 1, 2007; 48(3): 1201 - 1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kaji, T. Usui, S. Ishida, K. Yamashiro, T. C. B. Moore, J. Moore, Y. Yamamoto, H. Yamamoto, and A. P. Adamis Inhibition of Diabetic Leukostasis and Blood-Retinal Barrier Breakdown with a Soluble Form of a Receptor for Advanced Glycation End Products Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 858 - 865. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Antonetti, A. J. Barber, S. K. Bronson, W. M. Freeman, T. W. Gardner, L. S. Jefferson, M. Kester, S. R. Kimball, J. K. Krady, K. F. LaNoue, et al. Diabetic Retinopathy: Seeing Beyond Glucose-Induced Microvascular Disease Diabetes, September 1, 2006; 55(9): 2401 - 2411. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Kniep, C. Roehlecke, N. Ozkucur, A. Steinberg, F. Reber, L. Knels, and R. H. W. Funk Inhibition of Apoptosis and Reduction of Intracellular pH Decrease in Retinal Neural Cell Cultures by a Blocker of Carbonic Anhydrase. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 1185 - 1192. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |